LU91087I2 - Advate(Octocog alfa) soustotes ses formes protégées par le brevet de base. - Google Patents

Advate(Octocog alfa) soustotes ses formes protégées par le brevet de base.

Info

Publication number
LU91087I2
LU91087I2 LU91087C LU91087C LU91087I2 LU 91087 I2 LU91087 I2 LU 91087I2 LU 91087 C LU91087 C LU 91087C LU 91087 C LU91087 C LU 91087C LU 91087 I2 LU91087 I2 LU 91087I2
Authority
LU
Luxembourg
Prior art keywords
protein
factor viiic
compsn
polypeptide
new
Prior art date
Application number
LU91087C
Other languages
English (en)
Original Assignee
Chiron Corp
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27075219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91087(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/570,062 external-priority patent/US5004804A/en
Application filed by Chiron Corp, Novo Nordisk As filed Critical Chiron Corp
Publication of LU91087I2 publication Critical patent/LU91087I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU91087C 1984-01-12 2004-06-26 Advate(Octocog alfa) soustotes ses formes protégées par le brevet de base. LU91087I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/570,062 US5004804A (en) 1984-01-12 1984-01-12 Method and composition for preparation of factor VIIIC
US66491984A 1984-10-26 1984-10-26
EP85100223A EP0150735B2 (fr) 1984-01-12 1985-01-11 Composition protéique à activité coagulante et méthode de préparation de ladite composition

Publications (1)

Publication Number Publication Date
LU91087I2 true LU91087I2 (fr) 2004-08-26

Family

ID=27075219

Family Applications (4)

Application Number Title Priority Date Filing Date
LU91013C LU91013I2 (fr) 1984-01-12 2003-03-18 ReFacto (Moroctocog alfa) dans toutes ses formes couvertes par le brevet de base
LU91014C LU91014I2 (fr) 1984-01-12 2003-03-18 Kogentate (Octocog alfa) dans toutes ses formes couvertes par le brevet de base
LU91015C LU91015I2 (fr) 1984-01-12 2003-03-18 Recombinate (Rurioctocog alfa) dans toutes ses formes couvertes par le brevet de base
LU91087C LU91087I2 (fr) 1984-01-12 2004-06-26 Advate(Octocog alfa) soustotes ses formes protégées par le brevet de base.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
LU91013C LU91013I2 (fr) 1984-01-12 2003-03-18 ReFacto (Moroctocog alfa) dans toutes ses formes couvertes par le brevet de base
LU91014C LU91014I2 (fr) 1984-01-12 2003-03-18 Kogentate (Octocog alfa) dans toutes ses formes couvertes par le brevet de base
LU91015C LU91015I2 (fr) 1984-01-12 2003-03-18 Recombinate (Rurioctocog alfa) dans toutes ses formes couvertes par le brevet de base

Country Status (7)

Country Link
EP (3) EP0150735B2 (fr)
JP (5) JPH0826078B2 (fr)
AT (2) ATE224445T1 (fr)
DE (6) DE10399009I1 (fr)
DK (3) DK165506C (fr)
LU (4) LU91013I2 (fr)
NL (4) NL300118I2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
WO1985001961A1 (fr) * 1983-10-28 1985-05-09 Genetics Institute Production du facteur viii et des produits relatifs
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
EP0182448A3 (fr) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Production de facteur VIII et produits apparentés
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
JPH0788399B2 (ja) * 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
EP0272304B1 (fr) * 1986-06-24 1994-01-26 Novo Nordisk A/S Procede pour produire un complexe actif de coagulation des fragments du facteur viii
DE3769872D1 (de) 1986-07-11 1991-06-13 Miles Inc Herstellung von rekombinantem protein.
NO872932L (no) * 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
WO1988005825A1 (fr) * 1987-01-30 1988-08-11 Biogen N.V. Procede de production du facteur viii en grande quantite
CA1339946C (fr) * 1987-03-31 1998-07-07 Michael J. Griffith Methode d'ultrapurification pour les polypeptides
EP0294910B1 (fr) 1987-06-12 1996-09-11 Immuno Ag Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
US6140111A (en) * 1987-12-11 2000-10-31 Whitehead Institute For Biomedical Research Retroviral gene therapy vectors and therapeutic methods based thereon
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
JPH05500512A (ja) * 1989-09-14 1993-02-04 バクスター　インターナショナル　インコーポレーテッド 薬学的組成物を製造するための方法および装置
US5610033A (en) * 1990-04-25 1997-03-11 Novo Nordisk A/S Method of producing proteins with FVIII activity and/or FVIII derivatives
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
EP0965597A4 (fr) * 1996-12-27 2003-01-08 Mochida Pharm Co Ltd Medicaments diriges vers la membrane cellulaire
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
EP1418810A4 (fr) 2001-08-03 2006-08-02 Us Gov Health & Human Serv Traitement de l'hemophilie par voie orale
US7718787B2 (en) * 2002-10-18 2010-05-18 Lg Life Sciences Limited Gene families associated with cancers
EP1707634A1 (fr) 2005-03-29 2006-10-04 Octapharma AG Procédé pour l'isolation de protéines recombinantes
EP1739179A1 (fr) 2005-06-30 2007-01-03 Octapharma AG Transfection stable exempt de sérum et production des protéines recombinantes humaines dans des lignées cellulaires humaines
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
WO2011095604A1 (fr) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Prolongation de la demi-vie de protéines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
IE80858B1 (en) * 1983-03-31 1999-04-21 Scripps Research Inst New factor viii coagulant polypeptides
US4663280A (en) * 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
WO1985001961A1 (fr) * 1983-10-28 1985-05-09 Genetics Institute Production du facteur viii et des produits relatifs
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPH0634760A (ja) * 1992-07-15 1994-02-10 Hamamatsu Photonics Kk 放射線計測装置及び核医学診断装置

Also Published As

Publication number Publication date
JPS60185723A (ja) 1985-09-21
NL300153I1 (nl) 2004-09-01
DK13585A (da) 1985-09-11
ATE224445T1 (de) 2002-10-15
NL300120I1 (nl) 2003-06-02
DK13585D0 (da) 1985-01-11
EP0466199A1 (fr) 1992-01-15
EP0150735A3 (en) 1987-07-01
NL300118I2 (nl) 2004-06-01
DK38892A (da) 1992-03-25
LU91014I2 (fr) 2003-06-19
DE3588242D1 (de) 2002-10-31
EP0150735A2 (fr) 1985-08-07
ATE78871T1 (de) 1992-08-15
LU91015I2 (fr) 2003-06-19
DK38892D0 (da) 1992-03-25
DE10399010I1 (de) 2003-10-23
JPH0826078B2 (ja) 1996-03-13
JPH06105688A (ja) 1994-04-19
DE10399011I1 (de) 2003-10-23
NL300118I1 (nl) 2003-06-02
DK169708B1 (da) 1995-01-16
DK169724B1 (da) 1995-01-23
JPH04218399A (ja) 1992-08-07
DE3586402T2 (de) 1993-01-07
EP1006182A3 (fr) 2000-06-14
DE122004000028I1 (de) 2004-09-30
DE3588242T2 (de) 2004-03-11
EP0150735B2 (fr) 2004-01-07
DK150992A (da) 1992-12-17
DE3586402D1 (de) 1992-09-03
EP0466199B1 (fr) 2002-09-18
JP2000023670A (ja) 2000-01-25
NL300119I1 (nl) 2003-06-02
DE10399009I1 (de) 2003-10-23
EP1006182A2 (fr) 2000-06-07
LU91013I2 (fr) 2003-06-19
DE3586402T3 (de) 2004-12-23
JP2002186487A (ja) 2002-07-02
DK165506B (da) 1992-12-07
DK165506C (da) 1993-04-19
EP0150735B1 (fr) 1992-07-29
JPH0634760B2 (ja) 1994-05-11

Similar Documents

Publication Publication Date Title
LU91087I2 (fr) Advate(Octocog alfa) soustotes ses formes protégées par le brevet de base.
Pepys et al. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein
BR8606615A (pt) Polipeptideos complementares a peptideos ou proteinas tendo uma sequencia de aminoacidos ou sequencia de codificacao de nucleotidios conhecida ao menos parcialmente e metodos de projeto dos mesmos
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE149522T1 (de) Synthetische antigene zum nachweis von antikörpern gegen hepatitis c-virus
ATE113960T1 (de) Proteingewinnung.
DE68925199D1 (de) Peptide und polypeptide stammend von den submaxillaren drüsen der ratte, deren entsprechende monoklonale und polyklonale antikörper entsprechende hybridomen und verwendung dieser verbindungen in der diagnose bei bestimmungen und für pharmazeutische zwecke
DE3481861D1 (de) Antigen im zusammenhang mit der fruehzeitigen feststellung von schwangerschaft bei saeugern.
DE69426209D1 (de) Stannius- körperchen -protein, stanniocalcin
EP1132402A4 (fr) Fragments peptidiques a activite inhibitrice de la mort cellulaire
DE68925043D1 (de) Synthetische Peptide und deren Mischungen für den Nachweis von HIV-Antikörpern
ATE350398T1 (de) Protein s polypeptide und deren verwendungen
KR950018049A (ko) 사람 dna 토포이소머라제 제i형의 돌연변이체 단백질
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법